Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04766086 · ClinicalTrials.gov registry record · Phase 2
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT04766086 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 306 participants.
The verdict
NCT04766086, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Multivalent Group B streptococcus vaccine
- BIOLOGICAL Tetanus, diphtheria, and acellular pertussis vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04766086
The ClinicalTrials.gov registry entry for NCT04766086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04766086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04766086 about?
NCT04766086 is a clinical study titled "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women". This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
What is the current status of trial NCT04766086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2022-08-12. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT04766086?
The interventions under investigation include: Placebo (BIOLOGICAL), Multivalent Group B streptococcus vaccine (BIOLOGICAL), Tetanus, diphtheria, and acellular pertussis vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04766086?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.